The British Menopause Society (BMS) is the specialist authority for menopause and post reproductive health in the UK. The BMS educates, informs and guides healthcare professionals, working in both primary and secondary care, on menopause and all aspects of post reproductive health.

BMS guidelines prepared by the BMS medical advisory council in partnership with other specialist organisations and Royal Colleges, address key disorders and controversial topics relating to menopause and post reproductive health. They reflect new studies together with recent medical and scientific information from articles in professional journals, plus informal consensus.

The guidelines are evidence-based, comprehensively referenced and peer reviewed and they are regularly updated.

  • Management of unscheduled bleeding on hormone replacement therapy (HRT)
    This joint guideline has been prepared on behalf of the British Menopause Society, in partnership with the British Society of Gynaecological Endoscopy, British Gynaecological Cancer Society, College of Sexual & Reproductive Healthcare, Getting It Right First Time (GIRFT), Royal College of General Practitioners and the Royal College of Obstetricians & Gynaecologists.
  • Management of menopausal symptoms following treatment of gynaecological cancer
    This joint guideline has been prepared on behalf of the British Menopause Society, in partnership with the British Gynaecological Cancer Society.
  • Menopause and Long COVID
    Menopause and Long COVID share a range of overlapping symptoms and this can make it difficult to differentiate between the two to offer tailored support.  This guidance, developed by the Royal College of Nursing in collaboration with the British Menopause Society, is based on available evidence and clinical expertise.  It outlines principles of assessment, diagnosis, management and support to facilitate self-help and recovery.

The BMS is pleased to endorse the following guidelines:

  • ESHRE Guideline: management of women with premature ovarian insufficiency (POI)
    This European Society of Human Reproduction and Embryology guideline offers best practice recommendations for the care of women with with both primary and secondary POI. POI is a clinical condition defined by the loss of ovarian function indicated by irregular menstrual cycles together with biochemical confirmation of ovarian insufficiency before the age of 40.
  • ESE Clinical Practice Guideline for the evaluation and management of menopause and the perimenopause
    This European Society of Endocrinology guideline provides clinicians with practical guidance on the evaluation and management of women in menopause and beyond, including hormonal, non-hormonal, lifestyle and psychosocial interventions, with an emphasis on patient-centred care. Gender-affirming hormonal therapy is not included within this guideline because the therapeutic goals and risks of therapy in transwomen are distinct to those of hormonal therapy for menopause.
  • IMS Recommendations and Key Messages on Women’s Midlife Health and Menopause
    The International Menopause Society (IMS) recommendations and key messages on women’s midlife health, menopause and menopause hormone therapy (MHT) help healthcare professionals to optimise the support they offer women at this critical stage of life.  Developed following a rigorous systematic review of the literature, they provide evidence-based guidance across topics including lifestyle, midlife body changes, vasomotor symptoms, genitourinary syndrome of menopause, cardiometabolic health, bone health, cancers, dementia, premature ovarian insufficiency and sexual wellbeing.